Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Inotiv, Inc. Earnings Release 2004

Feb 17, 2004

34595_rns_2004-02-17_73087c61-6eba-4beb-af8c-b53f8e0398cd.zip

Earnings Release

Open in viewer

Opens in your device viewer

8-K 1 bas8kdec18.htm BIOANALYTICAL 8K - DECEMBER 18, 2003 Bioanalytical Systems, Inc. - Form 8K (dated 10/31/2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2003

BIOANALYTICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter)

Indiana 0-23357 35-1345024
(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2701 Kent Avenue West Lafayette, Indiana 47906-1382
(Address of principal executive offices) (Zip Code)
(765) 463-4527
(Registrant's telephone number, including area code)

Item 12. Results of Operations and Financial Condition.

MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation"

On December 18, 2004, Bioanalytical Systems, Inc. issued a press release providing information on earnings and other financial results for its fourth quarter of fiscal 2003 ended September 30, 2003. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default"

The information in this Form 8-K is being furnished and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Workstation"

SIGNATURES

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default"

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 16, 2004 Bioanalytical Systems, Inc. By: /s/ Michael P. Silvon Michael P. Silvon Chief Financial Officer (Interim)

MARKER FORMAT-SHEET="Head Major Center Bold 1" FSL="Default"

Exhibit Index

Exhibit No. Description

99.1 Bioanalytical Systems, Inc. press release, issued December 18, 2003.